{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:33:42Z","timestamp":1784086422324,"version":"3.55.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.ejim.2022.02.020","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T02:07:31Z","timestamp":1645841251000},"page":"33-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-3813","authenticated-orcid":false,"given":"Paula","family":"Jim\u00e9nez-Fonseca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1375-3488","authenticated-orcid":false,"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Arranz Arija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Manuel","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-8412","authenticated-orcid":false,"given":"Ana","family":"Callejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Cacho","family":"Lavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9566-9561","authenticated-orcid":false,"given":"Marinha","family":"Costa Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4101-5490","authenticated-orcid":false,"given":"Joaqu\u00edn","family":"Mosquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Rodrigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"S\u00e1nchez Morillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Vares Gonzal\u00e9z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Carmona-Bayonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejim.2022.02.020_bib0001","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejim.2022.02.020_bib0002","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3747\/co.25.4266","article-title":"Treatment algorithm in cancer-associated thrombosis: Canadian expert consensus","volume":"25","author":"Carrier","year":"2018","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.ejim.2022.02.020_bib0003","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","article-title":"SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)","volume":"22","author":"Mu\u00f1oz Mart\u00edn","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"10.1016\/j.ejim.2022.02.020_bib0004","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejim.2022.02.020_bib0005","unstructured":"National Comprehensive Cancer Network. NCCN guideline on cancer-associated venous thromboembolic disease. Version 1. 2020. Available at https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vte.pdf. Accessed March 11, 2021."},{"issue":"3","key":"10.1016\/j.ejim.2022.02.020_bib0006","doi-asserted-by":"crossref","first-page":"194","DOI":"10.7326\/0003-4819-153-3-201008030-00010","article-title":"The development of clinical practice guidelines and guidance statements of the American college of physicians: summary of methods","volume":"153","author":"Qaseem","year":"2010","journal-title":"Ann Intern Med"},{"issue":"22","key":"10.1016\/j.ejim.2022.02.020_bib0007","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American society of hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejim.2022.02.020_bib0008","first-page":"1","article-title":"Prediction and prevention of cancer-associated thromboembolism","volume":"25","author":"Khorana","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ejim.2022.02.020_bib0009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2022.02.020_bib0010","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.ejim.2022.02.020_bib0011","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1002\/cam4.3269","article-title":"Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: Results from a pre-specified subgroup analysis of the randomized CASSINI study","volume":"9","author":"Vadhan-Raj","year":"2020","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejim.2022.02.020_bib0012","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejim.2022.02.020_bib0013","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","article-title":"Efficacy of prophylactic low\u2013molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial","volume":"33","author":"Pelzer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.ejim.2022.02.020_bib0014","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3390\/cancers12082028","article-title":"Primary thromboprophylaxis in ambulatory pancreatic cancer patients receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Frere","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ejim.2022.02.020_bib0015","article-title":"Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"12","author":"Di Nisio","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejim.2022.02.020_bib0016","first-page":"159","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin Appl Thromb Off J Int Acad Clin Appl Thromb"},{"issue":"5","key":"10.1016\/j.ejim.2022.02.020_bib0017","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejim.2022.02.020_bib0018","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02431-2017","article-title":"Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK -rearranged non-small cell lung cancer","volume":"51","author":"Zugazagoitia","year":"2018","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ejim.2022.02.020_bib0019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cllc.2016.10.007","article-title":"ALK -rearranged non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism","volume":"18","author":"Zer","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejim.2022.02.020_bib0020","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2020.10.002","article-title":"High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1","volume":"141","author":"Mu\u00f1oz-Unceta","year":"2020","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejim.2022.02.020_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cllc.2019.06.012","article-title":"ROS1-rearranged Non\u2013small-cell lung cancer is associated with a high rate of venous thromboembolism: analysis from a phase II, prospective, multicenter, two-arms trial (METROS)","volume":"21","author":"Chiari","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ejim.2022.02.020_bib0022","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.lungcan.2020.01.017","article-title":"A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer","volume":"142","author":"Alexander","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejim.2022.02.020_bib0023","series-title":"Consensus SEOM Sobre la enfermedad thromboemb\u00f3lica in pacientes with cancer","article-title":"II","year":"2013"},{"key":"10.1016\/j.ejim.2022.02.020_bib0024","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010)."},{"issue":"4","key":"10.1016\/j.ejim.2022.02.020_bib0025","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1517\/14740338.5.4.553","article-title":"Incidence and management of bevacizumab-related toxicities in colorectal cancer","volume":"5","author":"Saif","year":"2006","journal-title":"Expert Opin Drug Saf"},{"issue":"11","key":"10.1016\/j.ejim.2022.02.020_bib0026","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2146\/ajhp080455","article-title":"Understanding and managing the possible adverse effects associated with bevacizumab","volume":"66","author":"Shord","year":"2009","journal-title":"Am J Health Syst Pharm"},{"issue":"25","key":"10.1016\/j.ejim.2022.02.020_bib0027","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ejim.2022.02.020_bib0028","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejim.2022.02.020_bib0029","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/jnci\/djs435","article-title":"Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis","volume":"104","author":"Proverbs-Singh","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"10.1016\/j.ejim.2022.02.020_bib0030","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1200\/JCO.2008.19.4274","article-title":"Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK national cancer research institute upper gastrointestinal clinical studies group","volume":"27","author":"Starling","year":"2009","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejim.2022.02.020_bib0031","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2022.02.020_bib0032","article-title":"Failure of the Ottawa score to predict the risk of recurrent venous thromboembolism in cancer patients: the prospective PREDICARE cohort study","author":"Girard","year":"2021","journal-title":"Thromb Haemost"},{"issue":"5","key":"10.1016\/j.ejim.2022.02.020_bib0033","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3324\/haematol.2019.222828","article-title":"Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. A systematic review and meta-analysis","volume":"105","author":"Delluc","year":"2020","journal-title":"Haematologica"},{"issue":"32","key":"10.1016\/j.ejim.2022.02.020_bib0034","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1200\/JCO.2013.51.7433","article-title":"Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the cancer-DACUS study","volume":"32","author":"Napolitano","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejim.2022.02.020_bib0035","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2022.02.020_bib0036","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res"},{"issue":"7","key":"10.1016\/j.ejim.2022.02.020_bib0037","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.ejim.2022.02.020_bib0038","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/jth.14561","article-title":"Extended treatment with edoxaban in cancer patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE cancer study","volume":"17","author":"Di Nisio","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"20","key":"10.1016\/j.ejim.2022.02.020_bib0039","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ejim.2022.02.020_bib0040","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jth.14752","article-title":"Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)","volume":"18","author":"Marshall","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2022.02.020_bib0041","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.thromres.2020.02.005","article-title":"Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism","volume":"188","author":"Schmidt","year":"2020","journal-title":"Thromb Res"},{"issue":"8","key":"10.1016\/j.ejim.2022.02.020_bib0042","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.3390\/cancers12082256","article-title":"Long-term treatment of cancer-associated thrombosis (CAT) beyond 6 months in the medical practice: USCAT, a 432-patient retrospective non-interventional study","volume":"12","author":"Mah\u00e9","year":"2020","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.ejim.2022.02.020_bib0043","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1182\/blood.2020005819","article-title":"Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis","volume":"136","author":"Mulder","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejim.2022.02.020_bib0044","doi-asserted-by":"crossref","first-page":"e373","DOI":"10.1055\/s-0038-1675577","article-title":"Cancer-associated thrombosis: beyond clinical practice guidelines-a multidisciplinary (SEMI-SEOM-SETH) expert consensus","volume":"2","author":"Pach\u00f3n","year":"2018","journal-title":"TH Open"},{"issue":"1","key":"10.1016\/j.ejim.2022.02.020_bib0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.thromres.2014.04.028","article-title":"Dose scaletion of low molecular weight heparin in patients with recurrent cancer-associated thrombosis","volume":"134","author":"Ihaddadene","year":"2014","journal-title":"Thromb Res"},{"issue":"25","key":"10.1016\/j.ejim.2022.02.020_bib0046","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1182\/blood-2017-03-742304","article-title":"How i treat recurrent venous thromboembolism in patients receiving anticoagulant therapy","volume":"129","author":"Schulman","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejim.2022.02.020_bib0047","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11912-019-0767-5","article-title":"Anticoagulation in cancer patients: a summary of pitfalls to avoid","volume":"21","author":"Patel","year":"2019","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.ejim.2022.02.020_bib0048","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.0452","article-title":"Association of inferior vena cava filter placement for venous thromboembolic disease and a contraindication to anticoagulation with 30-day mortality","volume":"1","author":"Turner","year":"2018","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.ejim.2022.02.020_bib0049","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","article-title":"PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma","volume":"8","author":"Perry","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2022.02.020_bib0050","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1160\/TH16-09-0680","article-title":"Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours","volume":"117","author":"Chai-Adisaksopha","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ejim.2022.02.020_bib0051","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","article-title":"Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study","volume":"126","author":"Donato","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejim.2022.02.020_bib0052","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ejim.2022.02.020_bib0053","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00277-014-2198-6","article-title":"Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study","volume":"94","author":"Kopolovic","year":"2015","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.ejim.2022.02.020_bib0054","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1055\/s-0038-1641150","article-title":"Renal Impairment, recurrent venous thromboembolism and bleeding in cancer patients with acute venous thromboembolism\u2014analysis of the CATCH study","volume":"118","author":"Bauersachs","year":"2018","journal-title":"Thromb Haemost"},{"issue":"12","key":"10.1016\/j.ejim.2022.02.020_bib0055","first-page":"3033","article-title":"Thrombosis, cancer and renal insufficiency: low molecular weight heparin at the crossroads","volume":"20","author":"Scott\u00e9","year":"2012","journal-title":"Support Care Cancer"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:36:44Z","timestamp":1760607404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620522000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":55,"alternative-id":["S0953620522000851"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2022.02.020","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2022.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}